10x Genomics Q2 Revenue Beats Expectations at $151 Million Despite Year-Over-Year Decline
10x Genomics reported second-quarter revenue of $151 million, beating analyst estimates of $146.5 million, according to company financial highlights. That revenue figure marks a 12.6% decline compared to the same period last year. Adjusted earnings per share reached $0.03, topping the consensus estimate of a $0.02 loss. Despite the financial beat, the market responded negatively, pushing the company’s valuation into focus at a $7.52 billion market capitalization.
Management Explains Revenue Step-Down and Atera Platform Transition
Management attributed the year-over-year revenue drop to lower instrument sales as customers held back purchases of current spatial products. Buyers are waiting for the upcoming Atera platform release, according to executive commentary from the earnings call. CEO Serge Saxonov and CFO Adam Taich addressed analyst inquiries regarding the timeline. Taich explained that the third quarter will feel the impact of this transition, while the fourth quarter will receive a significant boost from Atera instrument shipments. Manufacturing capacity remains the sole constraint on Atera shipments rather than a lack of customer demand, according to Saxonov.
Pro Tip: When evaluating platform transitions in life sciences companies, monitor manufacturing capacity updates alongside forward-looking guidance to gauge how quickly backlogs convert to recognized revenue.
Full-Year Guidance Lifted to $620 Million Amid Tenuous Academic Funding
Reflecting confidence in second-half catalysts, 10x Genomics raised its full-year revenue guidance midpoint to $620 million from $612.5 million, representing a 1.2% bump. Operating margins contracted to -12.9%, dropping from 17.4% in the prior-year quarter. Addressing market conditions during the Q&A session with J.P. Morgan analyst Jayden, Saxonov described the academic funding environment as tenuous. Grant approvals are not yet flowing completely through to direct purchases, and CFO Taich confirmed that no funding improvement is factored into the updated guidance figures.
Consumables Momentum and AI-Driven Demand Across Customer Segments
Underlying demand metrics remain resilient across core product lines despite the instrument pause. CEO Serge Saxonov highlighted strong momentum in Chromium consumables alongside growing engagement from both academic and biopharmaceutical customers. Furthermore, AI-driven demand is becoming a pervasive force across every customer segment. When questioned by Leerink analyst Puneet Souda about pricing strategy, Saxonov stated that the company is offering no unusual discounts or special incentive programs, noting that robust demand extends well beyond early adopters.
Did You Know?
10x Genomics shares traded at $57.67 following the earnings, climbing from $45.60 immediately prior to the earnings.
Frequently Asked Questions
What was 10x Genomics’ Q2 revenue?
10x Genomics reported Q2 revenue of $151 million, beating analyst estimates of $146.5 million.
Why did 10x Genomics experience a year-over-year revenue decline?
Management stated that lower instrument sales drove the decline as customers delayed purchases of existing spatial products to wait for the upcoming Atera platform.
What is the full-year revenue guidance for 10x Genomics?
The company raised its full-year revenue guidance midpoint to $620 million from $612.5 million.
What constrained Atera instrument shipments?
CEO Serge Saxonov stated that manufacturing capacity is the only constraint on Atera shipments, noting that underlying customer demand remains strong.
What are your thoughts on the Atera platform transition and 10x Genomics’ updated guidance? Leave a comment below to join the discussion.
Worth a look